Equities

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)137.50
  • Today's Change-2.50 / -1.79%
  • Shares traded40.25k
  • 1 Year change-56.35%
  • Beta-0.6714
Data delayed at least 20 minutes, as of Mar 28 2024 14:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-26.45m
  • Incorporated2006
  • Employees40.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151
  • Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Poolbeg Pharma PLC0.00-4.89m49.25m12.00--2.97-----0.0098-0.00980.000.03310.00----0.00-25.02---25.91--------------0.00-------100.60------
Celadon Pharmaceuticals PLC20.74k-8.06m53.94m----17.20--2,600.55-0.1306-0.13060.00030.04880.0016267.850.0248---64.68---71.16---29,080.42---40,384.18--1.84-12.450.6052--------------
Eco Animal Health Group Plc88.46m-1.62m57.92m228.00--0.710324.030.6548-0.024-0.0241.311.200.76641.923.41387,986.80-0.19496.03-0.26458.0243.0546.41-0.25447.892.261.220.043755.723.794.89246.94-35.90-4.43--
e-Therapeutics plc475.00k-8.27m64.28m38.00--1.94--135.32-0.0154-0.01540.00090.05680.0148--1.9212,500.00-25.79-33.25-27.10-35.11100.00100.00-1,741.90-1,490.90----0.0089---0.4193---2.53--24.22--
Redx Pharma PLC4.20m-33.16m71.96m101.00--18.47--17.13-0.099-0.0990.01260.010.0954--135.5541,603.96-75.26-52.99-166.19-88.10-----789.05-206.66----0.8405---77.52100.71-84.15--8.12--
Faron Pharmaceuticals Oy0.00-26.45m94.61m40.00---------0.4085-0.40850.00-0.21660.00-------287.97-213.06---963.12-----------12.02---------7.71---16.05--
Scancell Holdings Plc0.00-11.32m95.10m51.00---------0.0138-0.01380.00-0.01020.00----0.00-37.31-33.32-40.52-35.82-------817.98----1.73-------161.24--77.85--
Futura Medical PLC1.70m-5.11m122.09m12.00--15.12--71.67-0.0177-0.01770.00590.02680.1796--3.40141,954.20-53.82-75.22-66.35-106.1253.37---299.73-88,144.944.15--0.00-------17.93--67.85--
4Basebio PLC354.00k-6.28m122.93m----34.67--347.26-0.5094-0.50940.02870.27690.02960.39774.88---52.42---60.21--80.51---1,772.60--3.28-40.290.6683---20.71---59.20------
Creo Medical Group PLC29.23m-25.10m123.81m279.00--1.74--4.24-0.1139-0.11390.1260.19660.33181.874.14102,926.10-28.49---34.24--48.11---85.87--3.45--0.1177--7.98---9.52------
Animalcare Group Plc70.04m1.16m126.23m220.00110.121.5714.201.800.01910.01911.161.340.60472.515.06318,372.701.000.08771.210.102657.5952.041.660.15621.158.030.12232,044.86-3.25--2,651.95------
Data as of Mar 28 2024. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

11.25%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 31 Jan 20242.84m4.12%
Fj�rde AP-fondenas of 31 Oct 20232.58m3.74%
Sp-Fund Management Co. Ltd.as of 29 Feb 2024800.04k1.16%
OP Asset Management Ltd.as of 30 Jun 2023598.79k0.87%
Fondita Fund Management Co. Ltd.as of 31 Jan 2024330.49k0.48%
Danske Bank A/S (Investment Management Finland)as of 31 Jan 2024179.25k0.26%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2023159.68k0.23%
Aktia Varainhoito Oyas of 31 Oct 2021117.37k0.17%
Janus Henderson Investors UK Ltd.as of 31 Jan 2024100.00k0.15%
BG Fund Management Luxembourg SAas of 30 Jun 202341.74k0.06%
More ▼
Data from 31 Jul 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.